<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108511</url>
  </required_header>
  <id_info>
    <org_study_id>CLNB-009-04S</org_study_id>
    <nct_id>NCT00108511</nct_id>
  </id_info>
  <brief_title>Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides</brief_title>
  <official_title>Effect of Gemfibrozil on Serum GPI Phospholipase D and Triglycerides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the role of glycosylphosphatidylinositol-specific&#xD;
      phospholipase D (GPI-PLD) in triglyceride metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased fasting serum triglyceride levels are associated with an increased risk of coronary&#xD;
      artery disease. However, triglyceride levels in the postprandial state are a more sensitive&#xD;
      marker of coronary artery disease. Postprandial elevations in triglycerides result from a&#xD;
      decrease in the catabolism of triglyceride-rich lipoproteins, i.e. chylomicrons and very low&#xD;
      density lipoproteins (VLDL). This leads to an accumulation of atherogenic remnants of&#xD;
      triglyceride-rich lipoproteins. Although fasting triglycerides are the best predictors of&#xD;
      postprandial triglycerides, differences in fasting triglycerides only partially account for&#xD;
      the variation in magnitude of postprandial triglycerides. Recently, we have identified a new&#xD;
      protein involved in triglyceride-rich lipoprotein catabolism,&#xD;
      glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD). We have shown that elevated&#xD;
      levels of GPI-PLD are associated with increased fasting triglyceride levels. Serum GPI-PLD is&#xD;
      associated with high density lipoproteins (HDL) in the fasting state and exchange onto VLDL&#xD;
      in the postprandial state. Hepatic GPI-PLD decreases triglyceride-rich lipoprotein catabolism&#xD;
      in the liver. Hepatic and serum GPI-PLD levels are decreased by peroxisome proliferator&#xD;
      receptor (PPAR) alpha agonist treatment, which also reduces fasting and postprandial&#xD;
      triglycerides. The central hypothesis of this application is that variations in GPI-PLD&#xD;
      expression account for a portion of the differences in fasting and postprandial triglycerides&#xD;
      among humans.&#xD;
&#xD;
      The objective of this proposal is to determine the role of GPI-PLD in regulating fasting&#xD;
      triglycerides and post-prandial hypertriglyceridemia in humans. This will be accomplished by&#xD;
      conducting a double blind, placebo controlled study in humans examining the effect of&#xD;
      gemfibrozil on fasting and postprandial triglycerides in relationship to the variation and&#xD;
      changes in GPI-PLD before and after gemfibrozil.&#xD;
&#xD;
      Our specific objectives are:&#xD;
&#xD;
        -  1a) Determine the extent to which variations in GPI-PLD account for differences in&#xD;
           fasting and postprandial triglycerides&#xD;
&#xD;
        -  1b) Establish the degree to which the lowering of fasting and postprandial triglycerides&#xD;
           by gemfibrozil is accounted for by changes in GPI-PLD.&#xD;
&#xD;
        -  2) Quantify the changes in serum GPI-PLD and distribution of GPI-PLD among lipoproteins&#xD;
           in the postprandial state.&#xD;
&#xD;
      This will be the first prospective bench-to-bedside study examining the role of GPI-PLD in&#xD;
      triglyceride metabolism. This proposal will be the first in humans examining 1) the role of a&#xD;
      novel protein, GPI-PLD, in triglyceride metabolism, and 2) the effect of gemfibrozil, a drug&#xD;
      currently used clinically to lower triglyceride levels, on GPI-PLD levels in humans. It is&#xD;
      expected that the results from this study will increase our understanding of triglyceride&#xD;
      metabolism and develop new information in understanding the regulation of GPI-PLD and its&#xD;
      relationship to triglyceride metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date>September 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Hypertriglyceridemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 and &lt;75&#xD;
&#xD;
          -  Fasting triglycerides &gt;150 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fasting triglycerides &gt;600 mg/dl&#xD;
&#xD;
          -  LDL &gt;130 mg/dl&#xD;
&#xD;
          -  Concurrent lipid lowering therapy&#xD;
&#xD;
          -  Known hypersensitivity to gemfibrozil&#xD;
&#xD;
          -  Alcohol intake &gt;30 gm/day (2 drinks/day)&#xD;
&#xD;
          -  Fasting glucose &gt;125 mg/dl or known type 2 diabetes&#xD;
&#xD;
          -  AST or ALT &gt; 2.0 x upper limit of normal&#xD;
&#xD;
          -  Creatinine: men &gt;1.4 mg/dl, women &gt;1.3 mg/dl&#xD;
&#xD;
          -  Cancer treatment in the past 5 years (unless cured)&#xD;
&#xD;
          -  Infectious diseases including HIV or tuberculosis&#xD;
&#xD;
          -  Significant cardiac disease in the past 6 months (myocardial infarction, coronary&#xD;
             artery bypass graph, angioplasty, class 3 or 4 congestive heart failure, left bundle&#xD;
             branch block, third degree AV block)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure [SBP] &gt;180 or diastolic blood&#xD;
             pressure [DBP] &gt; 105 mm Hg)&#xD;
&#xD;
          -  Anemia (hematocrit &lt;40% men, &lt;35% women)&#xD;
&#xD;
          -  Any other significant systemic disease or medication that could interfere with&#xD;
             tolerance of medication or outcome&#xD;
&#xD;
          -  Any indication that a participant will be unable to adhere to the protocol&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Pregnant or breastfeeding females or a female who plans to become pregnant while&#xD;
             participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Roudebush VA Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>April 15, 2005</study_first_submitted>
  <study_first_submitted_qc>April 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2005</study_first_posted>
  <last_update_submitted>January 20, 2009</last_update_submitted>
  <last_update_submitted_qc>January 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2009</last_update_posted>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>lipoproteins</keyword>
  <keyword>triglycerides</keyword>
  <keyword>serum GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

